Using translational in vitro-in vivo modeling to improve drug repurposing outcomes for inhaled COVID-19 therapeutics
Madison Stoddard, Lin Yuan, Arijit Chakravarty
doi: https://doi.org/10.1101/2021.03.11.21253375
Madison Stoddard
1Fractal Therapeutics Inc, Cambridge, MA, USA
Lin Yuan
1Fractal Therapeutics Inc, Cambridge, MA, USA
Arijit Chakravarty
1Fractal Therapeutics Inc, Cambridge, MA, USA

Article usage
Posted March 12, 2021.
Using translational in vitro-in vivo modeling to improve drug repurposing outcomes for inhaled COVID-19 therapeutics
Madison Stoddard, Lin Yuan, Arijit Chakravarty
medRxiv 2021.03.11.21253375; doi: https://doi.org/10.1101/2021.03.11.21253375
Subject Area
Subject Areas
- Addiction Medicine (269)
- Allergy and Immunology (549)
- Anesthesia (134)
- Cardiovascular Medicine (1747)
- Dermatology (172)
- Emergency Medicine (310)
- Epidemiology (10779)
- Gastroenterology (583)
- Genetic and Genomic Medicine (2933)
- Geriatric Medicine (286)
- Health Economics (531)
- Health Informatics (1918)
- Health Policy (833)
- Hematology (290)
- HIV/AIDS (627)
- Medical Education (299)
- Medical Ethics (86)
- Nephrology (321)
- Neurology (2780)
- Nursing (150)
- Nutrition (431)
- Oncology (1454)
- Ophthalmology (440)
- Orthopedics (172)
- Otolaryngology (255)
- Pain Medicine (190)
- Palliative Medicine (56)
- Pathology (379)
- Pediatrics (864)
- Primary Care Research (333)
- Public and Global Health (5338)
- Radiology and Imaging (1002)
- Respiratory Medicine (722)
- Rheumatology (329)
- Sports Medicine (278)
- Surgery (327)
- Toxicology (47)
- Transplantation (149)
- Urology (125)